Anuh Pharma Limited on Friday announced that it has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its product Sulfadimethoxine. The company notified the stock exchanges about the development through an official filing.
According to the disclosure, the approval strengthens Anuh Pharma’s ability to supply high-quality Active Pharmaceutical Ingredients (APIs) that comply with stringent global regulatory standards. The CEP will allow the company to expand its presence in regulated international markets and offer improved reliability and supply security to its customers.
The company stated that this certification reinforces its commitment to delivering globally compliant pharmaceutical ingredients. The disclosure has also been published on Anuh Pharma’s website.
